Off The WHO Hook, Sanofi CEO Viehbacher Plans To Take Shantha's Vaccines To The World
This article was originally published in PharmAsia News
Executive Summary
HYDERABAD, India - Shantha Biotechnics, the Sanofi-owned Indian vaccines company, has received prequalification by the World Health Organization for a range of vaccines, including the pentavalent Shan 5 vaccine brand that had been previously disqualified by the world agency following detection of impurities in some batches
You may also be interested in...
Pharma’s Aim: Tap Innovation In Emerging Markets To Fix Woes At Home (Part 1 of 2)
Pharma must learn how to apply the best of its experiences in emerging markets to its traditional business, or, experts warn, invigorated competition from more nimble, faster-growing local players that have enjoyed success on their own turf will become a global threat.
Pharma’s Aim: Tap Innovation In Emerging Markets To Fix Woes At Home
Pharma must learn how to apply the best of its experiences in emerging markets to its traditional business, or, experts warn, invigorated competition from more nimble, faster-growing local players who have enjoyed success on their own turf will become a global threat.
In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 1 of 2)
Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.